GHENT, BELGIUM--(Marketwire - August 28, 2008) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today its results for the six month period ending 30 June, 2008, which have been prepared in accordance with the IAS 34 'Interim Financial Reporting' as adopted by the European Union.
